HEOR, Epidemiology & Market Access

Dr. Cunnington has over 20 years of experience as a pharmaceutical industry epidemiologist. She specializes in the generation of real-world evidence (RWE) in support of the development and life cycle management of pharmaceutical and vaccine products, with a particular focus on regulatory risk management strategies and product benefit-risk assessments. Dr. Cunnington’s research expertise includes the design, negotiation, and execution of real-world components of risk management plans for new product submission to regulators in the US, UK, EU, Japan, and South Korea, including studies of post-approval safety in the EU; post-marketing requirements and commitments in the US; and pregnancy registries. Prior to joining Analysis Group, she served in several senior epidemiology positions at pharmaceutical companies, including as the chair of GSK’s peer review forum for all pharmaceutical RWE projects; as a member of GSK’s Global Safety Board; as head of epidemiology at Novartis Vaccines; and as a managing board member of Innovative Medicines’ public-private partnership initiative to build an integrated European real-world data (RWD) network to monitor medication safety in pregnancy.

Mr. Xue consults on cases involving health economics and outcomes research (HEOR). He specializes in using health economics analyses to inform product launch strategies, as well as decision making in early-stage clinical development. Mr. Xue has extensive experience in the economic evaluation of health technologies across multiple therapeutic areas, including oncology, infectious diseases, autoimmune diseases, central nervous system diseases, ophthalmology, and gynecology. His work includes cost-effectiveness analysis, budget impact analysis, systematic literature review, indirect treatment comparison, evaluation of health care resource use, global value dossier, and market access strategy. He has led successful health technology assessment (HTA) submissions to the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Medicines Strategy Group (AWMSG). He has also developed global economic models across multiple indications and led country rollouts supporting market access in Europe, North America, and Asia.

Dr. Fillbrunn specializes in health economics and outcomes research (HEOR), biostatistics, and epidemiology. His expertise includes strategically developing and guiding the implementation of analytics throughout the entire product life cycle, including analyses of clinical trials and real-world health care data such as insurance claims, electronic health records, medical charts, and surveys. Dr. Fillbrunn’s contributions have informed clinical regulators and health care payers in both the US and global markets. His research has been published in several peer-reviewed journals and presented at clinical and health economic conferences. Prior to joining Analysis Group, Dr. Fillbrunn was a postdoctoral fellow at Harvard Medical School and Massachusetts General Hospital.

Dr. Xin specializes in health economics and outcomes research (HEOR). She provides expertise in decision-analytic modeling methods for health technology appraisals (HTA) and has led the design and implementation of cost-effectiveness and budget impact models in multiple countries. Dr. Xin’s work has also involved evidence synthesis such as network meta-analyses and matching-adjusted indirect comparisons, indirect treatment comparisons with individual-level patient data, clinical trial analyses, survey development, and patient-reported outcome (PRO) studies. Her work spans a broad range of disease areas, including oncology, immunology, dermatology, cardiovascular diseases, diabetes, and neurology. Prior to joining Analysis Group, Dr. Xin was a research associate at an academic institution, where she focused on trial- and model-based economic evaluations and PROs, as well as providing expertise on complex literature reviews and developing R Shiny applications for conducting network meta-analysis. Her work has been presented at clinical and economic research conferences and published in various peer-reviewed journals.